Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) Chairman Neil Desai offered 40,000 shares of the inventory in a transaction dated Tuesday, September third. The shares had been offered at a median worth of $1.71, for a complete transaction of $68,400.00. Following the completion of the transaction, the chairman now owns 1,171,543 shares of the corporate’s inventory, valued at roughly $2,003,338.53. The sale was disclosed in a doc filed with the SEC, which might be accessed via this hyperlink.
Neil Desai additionally just lately made the next commerce(s):
- On Monday, August fifth, Neil Desai offered 5,652 shares of Aadi Bioscience inventory. The shares had been offered at a median worth of $1.34, for a complete transaction of $7,573.68.
- On Thursday, August 1st, Neil Desai offered 15,415 shares of Aadi Bioscience inventory. The shares had been offered at a median worth of $1.50, for a complete transaction of $23,122.50.
- On Monday, July 1st, Neil Desai offered 31,348 shares of Aadi Bioscience inventory. The shares had been offered at a median worth of $1.45, for a complete transaction of $45,454.60.
Aadi Bioscience Inventory Efficiency
NASDAQ AADI opened at $1.83 on Friday. Aadi Bioscience, Inc. has a one yr low of $1.21 and a one yr excessive of $6.29. The corporate’s 50 day shifting common worth is $1.53 and its 200 day shifting common worth is $1.79. The agency has a market capitalization of $44.93 million, a price-to-earnings ratio of -0.72 and a beta of 0.69.
Aadi Bioscience (NASDAQ:AADI – Get Free Report) final posted its quarterly earnings information on Wednesday, August seventh. The corporate reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.17. The corporate had income of $6.18 million for the quarter, in comparison with analyst estimates of $6.33 million. Aadi Bioscience had a unfavourable web margin of 274.77% and a unfavourable return on fairness of 66.67%. Throughout the identical quarter final yr, the agency posted ($0.67) earnings per share. Promote-side analysts forecast that Aadi Bioscience, Inc. will submit -2.02 EPS for the present fiscal yr.
Institutional Buying and selling of Aadi Bioscience
Plenty of hedge funds have just lately made adjustments to their positions in AADI. Point72 Asia Singapore Pte. Ltd. bought a brand new stake in shares of Aadi Bioscience through the second quarter valued at roughly $37,000. Marquette Asset Administration LLC acquired a brand new stake in shares of Aadi Bioscience through the first quarter value roughly $135,000. Acuitas Investments LLC grew its place in shares of Aadi Bioscience by 10.8% through the second quarter. Acuitas Investments LLC now owns 352,483 shares of the corporate’s inventory value $515,000 after shopping for an extra 34,344 shares within the final quarter. Lastly, Decheng Capital LLC acquired a brand new stake in shares of Aadi Bioscience through the fourth quarter value roughly $1,063,000. Hedge funds and different institutional buyers personal 52.08% of the corporate’s inventory.
Wall Avenue Analyst Weigh In
A number of equities analysis analysts have issued studies on the inventory. HC Wainwright reaffirmed a “impartial” score on shares of Aadi Bioscience in a analysis notice on Wednesday, August twenty first. Piper Sandler Corporations lower shares of Aadi Bioscience from an “chubby” score to a “impartial” score and set a $1.75 goal worth on the inventory. in a analysis report on Tuesday, August twenty seventh. Piper Sandler lower shares of Aadi Bioscience from an “chubby” score to a “impartial” score and decreased their goal worth for the inventory from $5.00 to $1.75 in a analysis report on Tuesday, August twenty seventh. TD Cowen lower shares of Aadi Bioscience from a “purchase” score to a “maintain” score in a analysis report on Wednesday, August twenty first. Lastly, Jefferies Monetary Group lower shares of Aadi Bioscience from a “purchase” score to a “maintain” score and decreased their goal worth for the inventory from $11.00 to $1.50 in a analysis report on Wednesday, August twenty first. 5 analysts have rated the inventory with a maintain score, Based on information from MarketBeat, the corporate has a consensus score of “Maintain” and a consensus goal worth of $10.25.
Get Our Newest Inventory Evaluation on Aadi Bioscience
About Aadi Bioscience
Aadi Bioscience, Inc, a biopharmaceutical firm, engages in creating and commercializing precision therapies for genetically outlined cancers with alterations in mTOR pathway genes. Its lead drug product candidate contains FYARRO, a type of sirolimus protein-bound particles for injectable suspension for the remedy in grownup sufferers with superior unresectable or metastatic malignant PEComa.
Learn Extra
Obtain Information & Scores for Aadi Bioscience Day by day – Enter your e-mail deal with beneath to obtain a concise each day abstract of the most recent information and analysts’ rankings for Aadi Bioscience and associated firms with MarketBeat.com’s FREE each day e-mail publication.
